AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02628665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 630 nm laser irradiation (DIOMED)
Description: 630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
Study NCT01954420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention
Description: Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
Study NCT01954420 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Attention Control
Description: Standard care + Cancer education
Study NCT04494022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: contrast enhanced ultrasound
Description: Perflubutane enhanced ultrasound for evaluating hepatic tumor
Study NCT02326545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindLight
Description: MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
Study NCT02326545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online CBT
Description: Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
Study NCT04174950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
Study NCT04174950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model
Description: Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
Study NCT01640093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate, 250 mg (uncoated, current commercial tablet)
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
Study NCT01640093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 500 mg (coated, reformulated tablet)
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
Study NCT01640093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 250 mg (coated, reformulated tablet)
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
Study NCT01640093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
Study NCT01778179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tri-luma
Description: Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.
Study NCT04371224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: NAPOLI
Study NCT04371224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: NAPOLI
Study NCT04443998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone reducion forceps
Description: Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
Study NCT01247103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4316
Description: Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
Study NCT01247103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4316
Description: Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
Study NCT01247103 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD4316
Study NCT01778179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (CRY-AC3® device)
Description: Procedure performed at week 2.
Study NCT01778179 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy (CRY-AC3® device)
Description: Procedure performed at week 2.
Study NCT02497976 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: 400 mg
Study NCT02497976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT00277641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: 25 mg or 100 mg
Study NCT00277641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical tablets to study drug
Study NCT00669760 — intervention group
Intervention type: OTHER
Intervention: non-interventional study
Description: does not apply
Study NCT01178996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
Study NCT01178996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1000 mg (\<75 kg) or 1200 mg (>75 kg) daily with food divided in two doses orally for 48 weeks
Study NCT01178996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000 mg (\<75 kg) or 1200 mg (>75 kg) daily with food divided in two doses orally for 48 weeks
Study NCT01178996 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PEGinterferon alfa2a
Description: 180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
Study NCT01178996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGinterferon alfa2a
Description: 180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
Study NCT01178996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02960997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus, 2%
Study NCT02960997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus, 2%
Study NCT02960997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT02960997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Study NCT04526990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration
Study NCT04526990 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study NCT03487679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
Study NCT02382250 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Survey will be given to all participants
Study NCT03792425 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Connective tissue graft and implant placement
Description: Augmenting soft tissue with connective tissue graft
Study NCT01082380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
Study NCT02676128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twine Collaborative Care Application
Description: This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
Study NCT02676128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information-Motivation-Behavioral Skills Model of ART Adherence
Description: Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
Study NCT02511080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spot-On
Description: use of active hot measures
Study NCT01659541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of device
Description: The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
Study NCT00824538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT00824538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00824538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00824538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00318708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: clarithromycin 500 mg twice daily (Biaxin)
Study NCT00318708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
Study NCT00318708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
Study NCT00318708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo clarithromycin
Description: placebo clarithromycin twice daily
Study NCT04199039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect on Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction
Description: When the study started, the first 43 patients were assigned to the control group and the following 43 patients were assigned to the study group in the CVS ICU. ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted. ET fixation of the patients in the study group was performed with an ET holder (AnchorFast Oral Endotracheal Tube Fastener, Hollister, Liberlyville, USA) when they arrived at the CVS ICU.~The patients' SBP, DBP, HR and SpO2 values, which were displayed on the bedside monitor (Nihon Kohden, Tokyo), were recorded on the Hemodynamic Parameters Form just before, during, and at the end of endotracheal suction, and in the following 5th and 15th minutes.
Study NCT03342443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
Study NCT03342443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
Study NCT00702312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-salt educational programme
Description: Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
Study NCT00702312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-salt Bangladeshi educational programme
Description: A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
Study NCT00702312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-salt Bangladeshi educational programme
Description: A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
Study NCT00542698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of Physical Activity on Type II Diabetes Mellitus
Description: Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
Study NCT03461965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D printed model
Description: A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
Study NCT03461965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal Counselling
Description: Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
Study NCT03461965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Counselling
Description: Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
Study NCT01654575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 25mg/week for 16 weeks
Study NCT01654575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a week for 16 weeks
Study NCT02884115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzathine penicillin
Study NCT04786288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with lavender essential oil mixed in a carrier oil
Description: 22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage
Study NCT04786288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: massage with odourless baby oil
Description: odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
Study NCT01606488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Florbetapir F 18 (18F-AV-45)
Description: Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
Study NCT01606488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Study NCT00913627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Study NCT00913627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Study NCT00913627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03856580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternative long-acting PrEP injection strategies
Description: Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections
Study NCT03856580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth adherence app
Description: Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)
Study NCT03830970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canned beans of multiple varieties
Description: Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
Study NCT03830970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: White Rice
Description: Minute Rice Long Grain White Rice
Study NCT00700089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive intervention
Description: 8-20 assertive contacts after suicide attempt
Study NCT00700089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
Study NCT02285309 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Surgery and enoximone
Description: Does diastolic function change with cardiac surgery +/- enoximone
Study NCT00826293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization belt
Description: Patients receive true stabilization.
Study NCT00826293 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stabilization belt
Description: Patients receive sham stabilization.
Study NCT04313439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online cognitive therapy (I-CT)
Description: The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform.
Study NCT03193307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon® 30
Description: Run in period \& Treatment Period
Study NCT03193307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Day 18 \& 29 (Treatment Period)
Study NCT04462250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prescription Opioid Management App
Description: Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
Study NCT04264221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New management mode
Description: * New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use
Study NCT02113722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left cardiac sympathetic denervation
Description: Left cardiac sympathetic denervation via a video
Study NCT04433143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride capsules were taken orally
Description: Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.